跳至主要内容
临床试验/NL-OMON36315
NL-OMON36315已完成3 期

ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment - LNBO 219-381

Eli Lilly0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
Eli Lilly
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Male and female, adult outpatients aged *18 years who meet DSM-IV-TR diagnostic criteria for MDD as determined by clinical assessment by the Mini-International Neuropsychiatric Interview (MINI) and confirmed by the physician and who have experienced a partial treatment response to a course of SSRI treatment for at least 6 weeks with at least the last 4 consecutive weeks at a stable, optimized dose prior to Visit 2. Patients must have a score *16 on the GRID 17-Item Hamilton Rating Scale for Depression (GRID HAMD17) total score at Visit 1 and Visit 2. Patients will be determined to be partial responders by history, by the opinion of the investigator. Patients will also be required to have a rating indicating *75% improvement for their current SSRI treatment using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) at Visit 1.

排除标准

  • Exclusion criteria include any additional DSM-IV-TR Axis I condition other than major depression that was considered the primary diagnosis within 1 year of Visit 1; other primary Axis I anxiety diagnosis within the past year (including panic disorder, obsessive-compulsive disorder [OCD], posttraumatic stress disorder [PTSD], generalized anxiety disorder [GAD], and social phobia, but excluding specific phobias); current or previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder; have a serious or unstable medical condition; have any diagnosed medical condition that could be exacerbated by noradrenergic agents, including unstable hypertension, unstable heart disease, tachycardia or tachyarrhythmia, narrow-angle glaucoma, or history of urinary hesitation or retention; use of excluded concomitant medication; serious ideation/risk for harm to self or others; and pregnancy or breastfeeding status.

研究者

发起方
Eli Lilly

相似试验

进行中(未招募)
不适用
ot ApplicableMajor depressive disorder (MDD)MedDRA version: 14.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2010-020726-18-LTEli Lilly and Company600
进行中(未招募)
不适用
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentMajor depressive disorder (MDD)MedDRA version: 14.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2010-020726-18-PTEli Lilly and Company600
招募中
3 期
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who were Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentMajor Depressive Disorder
JPRN-jRCT2080221483Eli Lilly Japan K.K.
进行中(未招募)
1 期
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
EUCTR2010-020726-18-NLEli Lilly and Company600
进行中(未招募)
不适用
A Long-Term Study in SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophrenia
EUCTR2011-004327-13-ATEli Lilly and Company282